Hospital
Mercy Hospital Oklahoma City, INC
Mercy Hospital Oklahoma City, INC was paid $14.25M by Medicaid between Jan 2018 and Nov 2024, across 94 billing codes. Its largest line is 99285, emergency room visit (most serious) — 41% of everything it billed.
33Billing provider infoMERCY HOSPITAL OKLAHOMA CITY, INC
OKLAHOMA CITY, OK 73120
OKLAHOMA CITY, OK 73120
33aNPI1184721722assigned 09/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.25M
24GClaims137,087
24DCodes billed94
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Oklahoma
Rank by total paid#11 of 75
Median peer was paid$3.66M
This provider vs. median3.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,411 | $1.15M | |
| 2019 | 10,708 | $1.04M | |
| 2020 | 8,845 | $725K | |
| 2021 | 15,978 | $1.73M | |
| 2022 | 34,233 | $3.59M | |
| 2023 | 40,282 | $4.37M | |
| 2024incomplete | 13,630 | $1.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 41% | 18,235 | 18,097 | $5.79M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 11,456 | 11,403 | $2.70M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 16,090 | 15,978 | $2.61M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 9.1% | 9,333 | 9,194 | $1.29M |
| D9999 | Unspecified adjunctive procedure, by report | 3.0% | 546 | 545 | $427K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 4,607 | 4,518 | $232K |
| 80053 | Comprehensive metabolic panel | 1.2% | 14,317 | 14,142 | $168K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,033 | 21,680 | $138K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,153 | 1,123 | $91K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 161 | 82 | $88K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 25 | 25 | $77K |
| 62323 | <1% | 182 | 181 | $75K |
82 more codes
| 64493 | <1% | 164 | $73K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 191 | $69K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,095 | $39K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 289 | $36K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 666 | $35K |
| 62321 | <1% | 71 | $30K | |
| 81001 | <1% | 8,854 | $28K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,364 | $21K |
| 64635 | <1% | 22 | $20K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 225 | $18K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 104 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,689 | $12K |
| 80081 | <1% | 170 | $11K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 15 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,213 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 648 | $9K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 273 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 261 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,433 | $8K |
| 81025 | <1% | 1,143 | $8K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 137 | $7K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 217 | $6K |
| 84439 | <1% | 675 | $6K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 50 | $5K |
| 83690 | <1% | 822 | $4K | |
| 87081 | <1% | 649 | $4K | |
| 80061 | Lipid panel | <1% | 318 | $4K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 92 | $4K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 210 | $3K |
| 87634 | <1% | 50 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 107 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 100 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 897 | $3K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 122 | $3K |
| 87581 | <1% | 68 | $2K | |
| 87486 | <1% | 68 | $2K | |
| 87070 | <1% | 267 | $2K | |
| 84481 | <1% | 151 | $2K | |
| 80306 | <1% | 124 | $2K | |
| 87210 | <1% | 12 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 53 | $2K |
| 86140 | <1% | 408 | $2K | |
| 87653 | <1% | 50 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 188 | $2K |
| 74018 | <1% | 98 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 44 | $1K |
| 87511 | <1% | 39 | $1K | |
| 87481 | <1% | 40 | $1K | |
| 86850 | <1% | 87 | $737.50 | |
| 82950 | <1% | 139 | $600.15 | |
| 87807 | <1% | 12 | $598.69 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 12 | $542.76 |
| 82947 | <1% | 172 | $423.40 | |
| 72110 | <1% | 12 | $365.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13 | $356.72 |
| 85027 | <1% | 62 | $349.72 | |
| 83735 | <1% | 68 | $345.68 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 12 | $302.40 |
| 82728 | <1% | 25 | $299.40 | |
| 86900 | <1% | 86 | $235.71 | |
| 86901 | <1% | 85 | $230.76 | |
| 88304 | <1% | 13 | $225.04 | |
| 83655 | <1% | 13 | $159.90 | |
| 84484 | <1% | 13 | $155.26 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 128 | $153.76 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,623 | $127.88 |
| 83605 | <1% | 14 | $101.36 | |
| 81003 | <1% | 39 | $68.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,035 | $46.70 |
| 85652 | <1% | 23 | $45.60 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 116 | $44.40 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 346 | $8.56 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,692 | $2.46 |
| 64494 | 0% | 43 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 464 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 98 | $0.00 |
| 96376 | 0% | 177 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 64 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 15 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 278 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHAHNE, CHRISTOPHER (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Mercy Hospital Oklahoma City, INC | Yukon, OK | $36K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.